Publication:
Gene editing of PKLR gene in human hematopoietic progenitors through 5' and 3' UTR modified TALEN mRNA

Simple item page
dc.contributor.authorQuintana-Bustamante, Oscar
dc.contributor.authorFañanas-Baquero, Sara
dc.contributor.authorOrman, Israel
dc.contributor.authorTorres-Ruiz Raul, Raul
dc.contributor.authorDuchateau, Philippe
dc.contributor.authorPoirot, Laurent
dc.contributor.authorGouble, Agnès
dc.contributor.authorBueren, Juan A
dc.contributor.authorSegovia, Jose Carlos
dc.date.accessioned2020-03-27T17:16:59Z
dc.date.available2020-03-27T17:16:59Z
dc.date.issued2019-10-16
dc.descriptionTheauthorswouldliketothankMiguelA.MartinforthecarefulmaintenanceofNSGmice,andRebecaSa ́nchezandOmairaAlberquillafortheirtechnicalassistanceinflowcytometry.TheauthorsalsothankFundacio ́n Botı ́n forpromotingtranslationalresearchattheHemato-poieticInnovativeTherapiesDivisionoftheCIEMATes_ES
dc.description.abstractPyruvate Kinase Deficiency (PKD) is a rare erythroid metabolic disease caused by mutations in the PKLR gene, which encodes the erythroid specific Pyruvate Kinase enzyme. Erythrocytes from PKD patients show an energetic imbalance and are susceptible to hemolysis. Gene editing of hematopoietic stem cells (HSCs) would provide a therapeutic benefit and improve safety of gene therapy approaches to treat PKD patients. In previous studies, we established a gene editing protocol that corrected the PKD phenotype of PKD-iPSC lines through a TALEN mediated homologous recombination strategy. With the goal of moving toward more clinically relevant stem cells, we aim at editing the PKLR gene in primary human hematopoietic progenitors and hematopoietic stem cells (HPSCs). After nucleofection of the gene editing tools and selection with puromycin, up to 96% colony forming units showed precise integration. However, a low yield of gene edited HPSCs was associated to the procedure. To reduce toxicity while increasing efficacy, we worked on i) optimizing gene editing tools and ii) defining optimal expansion and selection times. Different versions of specific nucleases (TALEN and CRISPR-Cas9) were compared. TALEN mRNAs with 5' and 3' added motifs to increase RNA stability were the most efficient nucleases to obtain high gene editing frequency and low toxicity. Shortening ex vivo manipulation did not reduce the efficiency of homologous recombination and preserved the hematopoietic progenitor potential of the nucleofected HPSCs. Lastly, a very low level of gene edited HPSCs were detected after engraftment in immunodeficient (NSG) mice. Overall, we showed that gene editing of the PKLR gene in HPSCs is feasible, although further improvements must to be done before the clinical use of the gene editing to correct PKD.es_ES
dc.description.peerreviewedSíes_ES
dc.format.number10es_ES
dc.format.pagee0223775es_ES
dc.format.volume14es_ES
dc.identifier.citationPLoS One. 2019;14(10):e0223775.es_ES
dc.identifier.doi10.1371/journal.pone.0223775es_ES
dc.identifier.e-issn1932-6203es_ES
dc.identifier.issn1932-6203es_ES
dc.identifier.journalPloS onees_ES
dc.identifier.pubmedID31618280es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/9354
dc.language.isoenges_ES
dc.publisherBioMed Central (BMC)es_ES
dc.relation.publisherversionhttps://doi.org/ 10.1371/journal.pone.0223775es_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Unidades técnicas::Unidad de Citogenética Moleculares_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subject.mesh3' Untranslated Regionses_ES
dc.subject.mesh5' Untranslated Regionses_ES
dc.subject.meshAnimalses_ES
dc.subject.meshCells, Culturedes_ES
dc.subject.meshGene Editinges_ES
dc.subject.meshHEK293 Cellses_ES
dc.subject.meshHematopoietic Stem Cellses_ES
dc.subject.meshHumanses_ES
dc.subject.meshMicees_ES
dc.subject.meshPyruvate Kinasees_ES
dc.subject.meshTranscription Activator-Like Effector Nucleaseses_ES
dc.titleGene editing of PKLR gene in human hematopoietic progenitors through 5' and 3' UTR modified TALEN mRNAes_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
GeneeditingofPKLRgeneinhuman_2019.pdf
Size:
2.23 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Grupos de investigación